RxDoctor Payments Data

Geetha Komatireddy, MD

Rheumatology · Poplar Bluff, MONPI 1861421687

Payments from drug & device makers

$1,147in general payments, 2019–2025

Across 68 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$212
  • Pfizer$146
  • Bristol Myers Squibb$145
  • Amgen$131
  • Johnson & Johnson$100
  • GSK$79
  • plus $333 from 7 others

What the payments were for

  • Consulting fees$504%
  • Food & beverage$1,09796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,147 in reported general payments places this provider in the 35th percentile of 134 rheumatology providers in Missouri.

See all rheumatology providers in Missouri

Medicare billing

Part B allowed, 2024
$65,683
Medicare patients
225
Services billed
1,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept64$469,900
RinvoqUpadacitinib51$361,647
Humira PenAdalimumab52$352,881
Humira(Cf) PenAdalimumab30$236,412
OrenciaAbatacept21$117,418
XeljanzTofacitinib Citrate19$109,520
EnbrelEtanercept14$103,058
Orencia ClickjectAbatacept11$63,000
OtezlaApremilast13$48,158
OlumiantBaricitinib13$36,931
Hydroxychloroquine Sulfate438$8,553
MethotrexateMethotrexate Sodium801$8,524
Prednisone650$2,746
Leflunomide72$2,652
Cevimeline Hcl17$2,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$56$361,64751 claims
AmgenEnbrel, Otezla$131$151,21627 claims
E.r. Squibb & Sons, L.L.C.Orencia$63$117,41821 claims
PfizerXeljanz$146$109,52019 claims
Lilly USA, LLCOlumiant$47$36,93113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 134 rheumatology providers in Missouri.

Other rheumatology in Poplar Bluff

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →